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Abstract
Healthy ageing and longevity in humans result from a number of factors, including genetic background, favorable
environmental and social factors and chance.
In this article we aimed to overview the research on the biological basis of human healthy ageing and longevity,
discussing the role of epidemiological, genetic and epigenetic factors in the variation of quality of ageing and
lifespan, including the most promising candidate genes investigated so far. Moreover, we reported the
methodologies applied for their identification, discussing advantages and disadvantages of the different
approaches and possible solutions that can be taken to overcome them. Finally, we illustrated the recent
approaches to define healthy ageing and underlined the role that the emerging field of epigenetics is gaining in
the search for the determinants of healthy ageing and longevity.
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Background
The past few decades witnessed a growing social and
scientific interest in studies on human ageing and long-
evity. This interest is primarily due to the social burden
connected to the extraordinary increase of the elder
population in developed countries, which implies an
increase of the subjects which are not autonomous and
are affected by invalidating pathologies [1,2]. In Italy, for
instance, in 1961 the population aged 65 and older was
4.8 million (9.5% of the total population), while in 1981
this number increased up to 7.5 million (13.2% of the
total population) and in 2011 it grew up to 12.3 million
(20.3% of the total population). In addition, the popula-
tion aged 90 and older is growing at a faster pace as it
has triplicated in the last 20 years (data from population
Census and from http://www.istat.it). Proportionally, life
expectancy at birth increased from a medium value of
44 years (44.2 for males and 43.7 for females) in 1905 to
more than 80 years (79.4 for males and 84.5 for females)
in 2011. Similar figures are reported for all developed
countries, while in developing countries life expectancy
grows very fast as soon as infant mortality is reduced,
with the exception of some areas, namely in Africa,
where AIDS infection dramatically affects life expectancy
of adults [2].
Epidemiological evidence for a genetic component to
variation in human lifespan comes from twin studies
and family studies. By comparing life span in twins,
researchers have found that approximately 25% of the
overall variation in human lifespan can be attributed to
genetic factors [3-5], which become more relevant for
extreme longevity [6]. Conditioning factors, that arise in
the first part of life (socio-economic state of parents,
education and month of birth, which has been found to
reflect the environmental conditions during the prenatal
and early postnatal period), account for another 25% of
such variability; life circumstances at adult and old age
(including socio-economic status and medical assistance)
may account for about the remaining 50% [7].
Family-based studies demonstrated that parents, sib-
lings and offspring of long-live ds u b j e c t sh a v eas i g n i f i -
cant survival advantage when compared with the general
population [8-12]. Moreover, these studies indicated that
long-lived individuals and their children experienced a
lower incidence of age related diseases and a higher
degree of physical functioning and autonomy, when com-
pared to appropriate selected controls [13-15]. However,
how much of this reported survival advantage is due to
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remained unclear. By using the original approach to
adopt an intra-family control group, two different studies
[16,17] confirmed that a substantial contribution in the
familiarity observed in the above cited works was attribu-
table to genetic variation, so prompting the research to
deeply investigate the genetic variants favoring human
longevity.
In this paper we will review the literature on the studies
on the genetic of human longevity and the discussions
there has been on the different approaches that can be
used in this field. In addition, we will report the new
approaches that have been proposed to define the healthy
ageing, as the correct definition of healthy ageing is the
f i r s ts t e pt ou n d e r s t a n di t sg e netic basis. Finally, we will
outline some recent advance in the epigenetic studies of
ageing, as epigenetics, a bridge between genetics and
environment, might explain many aspects of ageing and
longevity.
Genetic variability and human longevity
The studies aimed to understand the genetic basis of
longevity in humans have been carried out under the
hypothesis that unfavorable genotypes should be dropped
out of the population by a sort of “demographic selec-
tion” [18] which finally results in an enrichment of favor-
able genotypes in the gene pool of long lived people
[19-21]. These studies have preliminarily faced the diffi-
culty of clearly defining the phenotype under study. In
fact, longevity is a dynamic phenomenon, where the defi-
nition changes in relation to the individual birth cohort.
Indeed, survival curves change with time, in relation to
the birth year of the cohort, thus medium age at death
progressively increases with time modifying the number
of subjects who can be defined as “long lived” [7,22]. In
this frame, demographic analyses allowed to show that
around the age of 90 years there is a clear deceleration of
the age related mortality rate [23], suggesting that the
subjects surviving to this age might be considered the
long lived subjects who have survived the “demographic
selection” mentioned above [24].
To date, many approaches have been adopted in order
to disentangle the genetic from the environmental effects
on human longevity, ranging from different sample
design to data analysis approaches [25]. Among the dif-
ferent sampling strategies adopted in the field of human
longevity research, a first distinction should be made
between family-based and population-based studies.
Family-based studies
At family level, the ASP design represents the typical non-
parametric strategy allowing both linkage and association
to be tested [26]. At population level, cross-sectional (or
case-control) cohort (longitudinal or follow-up) and case-
only studies represent the most common design strategies
providing important insights into the genetics of human
longevity. Family-based designs show the unique advan-
tages over population-based designs, as they are robust
against population admixture and stratification. On the
other hand, it is evident the difficulty to collect enough
families, especially for late-onset complex traits such as
lifespan, in which parental genotype information is usually
missing. Despite these problems, non-parametric linkage
analysis was attempted to localize genes implicated in
human longevity. One of the first attempts to identify
genetic regions co-segregating with the longevity pheno-
type by using an ASP approach has been carried out by
Puca and co-workers [27]. Scanning the whole genome by
applying non-parametric linkage analysis to long-lived sib-
pairs from USA they reported a region on chromosome 4
that could possibly harbor a gene affecting human longev-
ity. In a following association-based fine-mapping experi-
ment of the region, MTTP was identified as the gene most
probably responsible for the observed linkage peak
reported [28]. However, the association observed in this
sample could not be replicated neither in a larger French
sample of long-lived individuals nor in a sample of
German nonagenarians and centenarians [28,29].
Among the studies using an ASP approach it is worth
noticing the original study design adopted in the ECHA
project [30]. The authors, by using cousin-pairs born
from siblings who were concordant or discordant for the
longevity trait, analyzed two chromosomal regions
already known to encompass longevity-related genes.
Although no significant differences emerged between the
two groups of cousin-pairs (probably due to insufficient
sample size) this study provided important insights to
better dimension future sampling campaigns to study-
genetic basis of human longevity. In particular the GEHA
project [31] was launched in 2004 and was aimed to the
sampling of an unprecedented number (2500) of nona-
genarians sib-pairs from all over the Europe, to be ana-
lyzed for selected chromosomal regions previous related
to the longevity trait, and for discovering new regions by
a whole genome approach. Behind the scientific results
still to be published, GEHA clearly represents an example
of standard recruitment methodology, both for collecting
biological samples and phenotypic information by home-
based questionnaires, the last very crucial for the defini-
tion of phenotype [31].
Population case-control studies
Population case-control studies comparing long lived
samples with younger controls of the same population
may provide a powerful and more efficient alternative,
especially when associated to the recent advances in
genomic and statistical techniques. They are more
powerful than family designs for detecting genes with
low effect and gene-gene interactions [32]. However,
these cross-sectional studies may suffer from the lack of
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confound comparisons between very old people (for
example centenarians) and younger cohorts [33]. The
problem is hindered by the rapid changes of human
societies that increase the level of population heterogene-
ity, thus introducing a further complicating factor. To
cope with these problems, algorithms which integrate
g e n e t i ca n dd e m o g r a p h i cd a t ah a v eb e e np r o p o s e d
[22,24,34,35]. Genetic-demographic methods allow the
estimation of hazard rates and survival functions in rela-
tion to candidate alleles and genotypes. In such a way it
is possible to compare survival functions between indivi-
duals carrying or not carrying a candidate allele or geno-
type without introducing arbitrary age classes, and taking
into account cohort effects in mortality changes. Further-
more, the addition of demographic to genetic data not
only is able to reveal sex- and age-specific allelic effects,
but also permit a rational definition of the age classes to
be screened [24]. Moreover, from the application of
genetic-demographic model to longevity association stu-
dies, it emerged that genetic factors influence human sur-
vival in a sex- and age-specific way. In fact, in agreement
with demographic data, genetic variability plays a stron-
ger role in males than in females and in both genders its
impact is especially important at very old ages [6,17,24].
Multi-locus approaches
Most gene-longevity association studies have focused on
a single or a few candidate genes. However, common
genetic variants with important effects on human longev-
ity are unlikely to exist because of the rather low genetic
contribution to the trait. In addition, given the complex-
ity of the trait, the main effects of the individual loci may
be small or absent, while multiple genes with a small
effect may interact in an additive manner and affect sur-
vival at old ages. In such a case, a single-locus approach
may not be suitable, failing in finding positive results of
associations. Thus, given the technical improvement of
typing techniques, multi-locus association approaches
which takes into account epistatic interactions among
different genes, have become of age [36].
These approaches represent specific and important sta-
tistical challenges. A flexible framework to tackle these
challenges and for modeling the relationship between
multiple risk loci and a complex trait makes use of logis-
tic regression techniques [24,37]. Since from a statistical
point of view epistasis corresponds to an interaction
between genotypes at two or more loci, the same regres-
sion techniques have been easily extended to the analysis
of gene-gene and gene-environment interactions in com-
plex phenotypes, both at genome-wide and smaller scale
studies level [38,39].
In some studies, different loci clustered in haplotypes
are analyzed. In general haplotype-based association
analysis brings new possibilities and difficulties. They
exhibit more power than single-marker analysis for
genetic association studies since they incorporate linkage
disequilibrium information [40-42]. Conversely, the main
difficulty is that haplotypes are often not directly observa-
ble, especially for late-onset complex traits such as life-
span, owing to phase uncertainty. Methods based upon
likelihood can be extended to deal with kind of problem,
most conveniently by use of the EM algorithm. Among
these, the score tests proposed by Schaid et al. [43] are
the most popular. Among the methods developed for
haplotype-based multi-locus analysis of human survival,
the original studies carried out by Tan et al. involving
both cross-sectional [44] and cohort [45] designs studies
of unrelated individuals are worth noticing.
Further improvements in high-throughput technology,
associated to the recent advances in genomic knowledge,
have made whole genome genotyping (> 100,000 SNPs)
more accessible. Indeed, GWAS are at present widely
used to find genetic variants contributing to variation in
human lifespan [27,46-52]. In particular, Sebastiani and
co-workers, consistently with the hypothesis that the
genetic contribution is largest at the oldest ages and
that long-lived individualsa r ee n d o w e dw i t hm u l t i p l e
genetic variants with a single small effect, undertook a
genome-wide association study of exceptional longevity,
building a genetic profile including 281 SNPs able to
discriminate between 800 centenarians cases and 900
healthy controls. The “genetic signatures of exceptional
longevity” and relative subject-specific genetic risk pro-
file which were obtained can provide important insights
to dissect the unique complex phenotype into sub-phe-
notypes of exceptional longevity.
From a statistical point of view, the analysis of GWAS
data presents several statistical challenges including data
reduction, interaction of variables and multiple testing.
Although these challenges are new to statistics, the mag-
nitude of the present datasets is unprecedented.
After all these considerations, the most reasonable
approach, for taking into account a great number of sin-
gle polymorphisms spread along the genome without
losing the biological relevance of candidate genes in bio-
chemical pathways, which may be reasonably related to
the trait, seems to be to use a candidate regions
approach combined with a minimal number of “tagging”
SNPs, efficiently capturing all the common genetic var-
iation in the assayed genomic region [24,53-56]. This
hybrid tagging-functional approach, by selecting the
maximally informative set of tag SNPs in candidate-
gene/candidate region for an association study, promises
to shed a light in the genetic determinants of complex
traits in general, and hopefully in human longevity too
[57].
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longevity
By using the approaches described above, many candi-
date genes have been investigated to identify alleles that
are either positively or negatively selected in the cente-
narian population as consequence of a demographic pres-
sure. For many years, genetic analyses were focused on
single genetic variants, by using the classical “candidate
gene” approach. Candidates were found among human
orthologous of experimental model genes, where the
e x i s t e n c eo fs p e c i f i cm u t a t i o n s( age-1, daf2, sir2, methu-
selah, p66) able to extend or reduce lifespan has been
reported [58-62]. In laboratory models, all the longevity
genes identified have primary roles in physiological pro-
cesses and especially in signal transduction; therefore it
seems that natural selection does not select for genes
that cause ageing in these organisms, but rather ageing
occurs as a result of pleiotropic effects of genes that spe-
cify other fundamental processes.
In providing these insights, invertebrate studies moti-
vated a lot the search for human genes involved in longev-
ity and provided candidate genes, sometime successfully
found associated with human longevity too (i.e. KLOTHO,
FOXO3a, SIRT3; UCPs; [20,63-66]. However, these studies
revealed also many challenges and claimed for caution
that should be used when investigating human candidate
genes identified by their orthology in animal models [33].
Another important category of candidate genes for ageing
research are those involved in age-related diseases (in par-
ticular, cardiovascular diseases, Alzheimer’s, cancer and
auto-immune diseases) and genes involved in genome
maintenance and repair (in particular, those involved in
premature ageing syndromes such as Werner syndrome).
The underlying hypothesis is that long lived persons
should not present in their DNA any risk factors involved
in pathologies. On the contrary, long lived individuals har-
bor genetic risk factors for age-related diseases [67,68] as
recently underlined also by GWAS data, reporting as very
long lived individuals share the same number of risk alleles
for coronary artery disease, cancer, and type 2 diabetes
than younger controls from the same population, thus
suggesting that human longevity is not compromised by
t h ec u m u l a t i v ee f f e c to fas e to fr i s ka l l e l e sf o rc o m m o n
disease [69]. These studies support the existence of buffer-
ing mechanisms operating in the determination of human
longevity, probably through the presence of favorable gen-
otypes contrasting the deleterious effect of age-related dis-
ease genes: as a result, the frequency of deleterious
genotypes may increase among individuals with extreme
lifespan because their protective genotype allows disease-
related genes to accumulate [70].
Recently, from the study of a single gene and starting
again from the evidences in experimental models, which
suggest the existence of evolutionary conserved networks
that regulates lifespan and affects longevity across species,
research moved into the study of whole metabolic path-
ways, where to find candidate genes for human longevity.
From worms (C. elegans), to fruit flies (Drosophila), and
mammals (mouse), pathways related to the regulation of
energy homeostasis, cell maintenance, nutritional sensing,
stress response signalling to internal or external environ-
mental insults, by an efficient non inflammatory response,
and DNA repair/maintenance have been shown to criti-
cally modulate lifespan [62,71] so harboring interesting
candidate genes for longevity research. The insulin/IGF-1
pathway and downstream effectors, such as FOXO, are
among of the most promising in this sense. Mutations
affecting this pathway show effects on longevity from
invertebrates to mammals, with several longevity mutants
altering key components of the pathway, as for example
the increased lifespan of mice heterozygous for the IGF1
receptor knockout1 [72]. Moreover, the downstream tran-
scription factor DAF-16 (FOXO) regulates the expression
of several genes involved in stress resistance, innate immu-
nity, metabolic processes and toxin degradation [73].
Other interesting pathways for human longevity are repre-
sented by the TOR signalling, a major nutrient-sensing
pathway, whose genetic down-regulation can improve
health and extend lifespan in evolutionarily distant organ-
isms such as yeast and mammals [74] and the recently
deep investigated UCP pathway, a family of inner mito-
chondrial membrane proteins responsible for uncoupling
substrate oxidation from ATP synthesis, whose expression
was demonstrated to affect lifespan from fruit flies to
mouse, somehow mimicking the metabolic and lifespan
effects of caloric restriction (see [65] and references
therein).
In humans, the most relevant results found by associa-
tion studies in long lived cohorts, identified genes involved
in GH/IGF-1/Insulin signaling (GHR, IGF1R, FOXO3A),
antioxidant (SOD1, SOD2, PON1, FOXO3A), inflammatory
(IL6, CETP, Klotho) pathways, silencing (SIRT1 and
SIRT3), elements of lipid metabolism (APOE, APOB, ACE,
APOC3, MTTP) and stress resistance (HSPA1A and
HSPA1L) [[19,33,75-81] and references therein]. However,
most of these results, with the exception of APOE and
FOXO3A, were not reproduced in some of the replication
studies [29,82], probably because of problems in study
design and publication bias. This points to the need of lar-
ger populations for case-control studies in extreme long-
evity, use of replication cohorts from different populations
and appropriate multiple comparisons tests to reduce the
bias of these kind of studies [83].
Functional consequences of genetic variants associated
with human longevity
Coupled with the rapid advances in high-throughput
sequencing technologies, it is now feasible to compre-
hensively analyze all possible sequence variants in
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and to investigate the functional consequences of the
associated variants. A better understanding of the
functional genes that affect healthy longevity in
humans may lead to a rational basis for intervention
strategies that can delay or prevent age-related dis-
eases. Genome-wide expression profiles in different tis-
sues reported changes of gene expression occurring
with age. In this sense, two main works deserve atten-
tion. Kerber and collaborators, who analyzed the gene
expression profiles of 2151 house-keeping genes in cul-
tured cell lines from 104 adults belonging to 31 Utah
families, aged 57-97 years, searching for stable varia-
tion in gene expressions that affect or mark longevity.
They found different genes exhibiting associations with
either mortality or survival [84], 10% decreased in
expression with age, and 6% increased with age. Signif-
icant association both with age and survival was
observed for CDC42, belonging to the DNA repair
pathway and CORO1A, an actin-binding protein with
potentially important functions in both T-cell mediated
immunity and mitochondrial apoptosis [85], underlying
the potential importance of these metabolic pathway in
longevity determination. More recently, Slagboom and
co-workers [81] compared the expression profiles of
candidate genes in a limited number of subjects (50
for each group) among offspring of long-lived subjects
and their partners. Among the differentially expressed
genes, they observed a decreased expression of genes
in the mTOR pathway in the members of long-lived
families. Although it is likely that epigenetic factors
m a ya l s op l a yal a r g er o l e[ 8 6 ]a n dt h er e s u l t ss h o u l d
be replicate in a larger sample, it is clear that by com-
bining the molecular epidemiological studies with a
genomic approach may provide a step further towards
the identification of early and possibly causal contribu-
tions to the ageing and human longevity process.
The special case of the mitochondrial genome
Human ageing is characterized by a gradual reduction in
the ability to coordinate cellular energy expenditure and
storage (crucial to maintain energy homeostasis), and by
a gradual decrease in the in the ability to mount a suc-
cessful stress response [87]. These physiological changes
are typically associated with changes in body composition
(i.e. increase in fat mass and the decline in fat-free mass),
and with a chronic state of oxidative stress with impor-
tant consequences on health status [88]. Mitochondrial
function is crucial in these processes, being mitochondria
the main cellular sites controlling energy metabolism and
the redox state. Mitochondria are considered as key com-
ponents of the ageing process, playing a pivotal role in
cell survival and death since they contribute to many cel-
lular functions, including bioenergetics, protection from
oxidative damage, maintenance of mtDNA and cell death
[89]. Moreover, in addition to ATP production, mito-
chondria form a complex metabolic network which is
crucially involved in glucose sensing/insulin regulation,
intracellular Ca2+ homeostasis and many metabolic sig-
naling pathways [90]. On the other hand, mitochondria
are the major producers of ROS and at the same time
targets of ROS toxicity. Consequently, the maintenance
of a healthy mitochondria population represents a major
target of a well functioning organism, for preserving
many physiological functions, such as neurotransmission
[91]. Starting from the important role of this organelle in
the cell homeostasis, the effect of both inherited and
somatic variability of mtDNA in ageing and longevity has
been deeply investigated, resulting complex and some-
time controversial [92].
An accumulation of mtDNA somatic mutations occurs
with age, and many studies have reported an association
between mtDNA mutations and ageing, particularly in
post-mitotic neuronal cells [93]. A number of mutations
not associated to diseases have been fixed along time in
the mtDNA sequence, to form a series of population-spe-
cific lineages that can be identified by the presence of con-
served groups of haplotypes (haplogroups). These
germline inherited mtDNA variants (haplogroups and
their subclassification into subhaplogroups on the basis of
specific mutations identified by sequence analysis of the
D-loop region) are used for tracing back the origin of
populations or in forensic analyses [94]. Considered bio-
chemically neutral, the mtDNA inherited variability is
probably able to differently modulate the mitochondrial
metabolism [95]. mtDNA haplogroups have been posi-
tively associated with mitochondrial, complex diseases and
ageing [96,97]. In particular, in Caucasians the haplogroup
J is over-represented in long-living people and centenar-
ians, thus suggesting a role for this mtDNA variant in
longevity [98]. As for somatic variations, tissue specific
mutations occurring in the mtDNA control region have
been proposed to provide a survival advantage, i.e. the
C150T transition [99]. Data analyzing the occurrence and
accumulation of C150T mutation in centenarians’ relatives
and long lived sib pairs demonstrated a genetic control on
the mtDNA heteroplasmy (i.e. the presence of different
molecule of mutant/wild type mtDNA), suggesting the
existence of nuclear genetic factor influencing their accu-
mulation [100,101]. The observation that the nuclear gen-
ome contributes to mtDNA heteroplasmy marks the
importance of the mitochondrial-nucleus cross-talk in
modulating mitochondrial function and cellular homeosta-
sis and, consequently, quality of ageing and lifespan [102].
Such a nuclear-mitochondrial cross-talk was firstly
observed in yeast, where a compensatory mechanism,
named “retrograde response” has been described, allowing
to mutant strains of yeast to cope with mtDNA impair-
ments by up-regulating the expression of stress-responder
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lifespan.
The first experimental evidence that a similar mechan-
ism has been maintained in higher organisms, including
humans, comes from cytoplasmic hybrid or cybrid
experiments (i.e. cell lines differ only in the source of
their mtDNA), where it was found that cells character-
ized by different mtDNA haplogroups, differently
expressed stress responder nuclear genes [104,105], thus
suggesting that the retrograde response mechanism may
represent an evolutionary conserved strategy for the age-
related remodeling of organismal functions.
On the whole, although the involvement of mtDNA
variability in ageing and longevity is undisputed, the role
of mtDNA and its mutations, either inherited or somati-
cally acquired, in human longevity is far from being clear.
The use of high-throughput technologies and the exten-
sive analysis, possibly at the single cell level, of different
tissues and cell types derived from the same individual will
help in disentangling the complexity of mtDNA in ageing
and longevity.
The maintenance of telomere length
Genomic instability has been widely recognized as a cru-
cial mechanism in both ageing and age-related diseases.
The progressive shortening of telomeres, probably the
most important marker of chromosome integrity, is asso-
ciated with increased risk of several age-related disease
comprised cancer and mortality [106,107]. Telomeres play
a central role in maintaining the chromosome stability,
preventing the inappropriate activation of DNA damage
pathways, and regulating cell viability, by triggering signals
of ageing to normal cells to senesce when telomeres stop
their functioning [108]. Their length is controlled by telo-
merase. In normal human cells telomerase is expressed in
stem cells, cells that need to actively divide (like immune
cells) and is barely, or not expressed at all in differentiated
somatic cells. However, higher expression of telomerase
strongly correlated with carcinogenesis, with approxi-
mately 85%-90% of human cancers showing higher enzy-
matic activity [109]. Furthermore, suppression of
telomerase activity in telomerase-positive cancer cells
results in cell death and tumor growth inhibition [110],
highlighting the critical role of telomerase in facilitating
and enabling cancer cell proliferation. On the contrary,
high telomere stability correlates with human longevity,
with healthy individuals showing significantly longer telo-
meres than their unhealthier counterparts [68,111]. Longer
telomeres are associated with protection from age-related
diseases, better cognitive function and lipid profiles, thus
may confer exceptional longevity [112]. The understanding
of the complex tradeoff between cancer development
and long life in relation to telomere maintenance repre-
sents one of the most intriguing challenges for researchers
in human longevity. Considering these evidences,
centenarians may represent the best example of a well pre-
served telomere length, harboring the right compromise of
having longer telomeres and never have been affected by
cancer or survived to a cancer episode, so may represent
optimal control population for association studies aimed
to disentangle the complex role of telomere maintenance
in age-related diseases and ageing.
Successful ageing and frailty
Although ageing is a general phenomenon, it is clear that
a great inter-individual variability on the rate and quality
of ageing can be observed [33]. Following the paradigm
“Centenarians as a model for healthy ageing”, centenarian
studies have allowed to identify a number of characteris-
tics associated with extreme longevity. For example, non-
agenarian and centenarian men are generally taller and
heavier than women of corresponding age and have a
greater amount of muscle and trunk fat, whereas women
are small and show a marked peripheral adipose distribu-
tion [113]. Furthermore, food preferences, marital status,
personality and coping strategies, levels of family support,
and education have all been linked with successful late-
life ageing [113-118]. However, whether centenarians
represent healthy ageing still remains an open question.
Franceschi and co-workers recognized that on the basis
of their functional status centenarians might be classified
into three categories [119]. Most of them suffer of dis-
abilities or diseases [120], and in general they experience
al o s so fi n d e p e n d e n c e[ 1 ] ,b u tam i n o r i t yo ft h e ma r e
still in quite a good health. According to this perspective,
centenarians are not the most robust subjects of their age
cohort, but rather those who better adapted and re-
adapted from both biological and non-biological point of
view, and in general they constitute a very heterogeneous
group of individuals [119]. Hence several studies
searched for indicators of health and functional status in
old and very old subjects by which objective phenotypes
could be defined [121-126]. From these studies the con-
cept of frailty emerged as a distinct clinical entity, charac-
terized by a state of vulnerability for adverse health
outcomes, such as hospitalization or death, and therefore
correlated to co-morbidity, disability and increased mor-
tality hazard [127]. The “frailty” syndrome of the elderly
is mainly correlated to the decline of homeostatic capa-
city of the organism, which implies the decline of differ-
ent physiological systems, such as the neuromuscular and
the cognitive systems, and which leads to a significant
increase of disability, comorbidity and death risk [121].
The frailty declines with age and make less efficient the
metabolic pathways for the conservation, the mobiliza-
tion and the use of the nutrients, thus representing the
physiologic precursor and etiologic factor in disability,
due to its central features of weakness, decreased endur-
ance, and slowed performance [121]. Therefore, the
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recognize homogeneous population groups enriched of
genetic risk factors predisposing to a poor quality of age-
ing. How to measure frailty? First of all, because popula-
tion specificity was demonstrated in the quality of ageing
[128], it is necessary to carry out population specific sur-
veys to define the tools which are able to highlight within
each population groups of subjects with homogeneous
“ageing phenotype”. Among the methodologies used to
classify homogenous subgroups within each population,
the cluster analysis proved to be very useful to identify
groups of subjects homogeneous with respect to chosen
variables. As for the parameters to be used for the classi-
fication, cognitive, psychological and functional measures
turned out to be the most effective to identify the frailty
phenotype, since these parameters condense most of the
frailty cycle that occurs in the elderly [122]. In particular,
classification variables useful for grouping individuals
respect their frailty status are represented by SHRS, ADL,
HG strength and MMSE [129,130]. This kind of classifi-
cation, which allows to define three main frailty groups
(i.e. frail, pre-frail and non frail subjects), was firstly
applied to a Southern Italian population, and proved to
be able to foresee health status by the analysis of perspec-
tive survival. In particular, a longitudinal study showed a
differential incidence of mortality after 18 and 36 months
follow-up of the different groups identified [129]. The
proposed classification was replicated in two large longi-
tudinal Danish samples [130], where different ageing
conditions had been previously described [128], confirm-
ing the predictive soundness after a 10-years follow up.
In addition, in the same work the differential effect of
distinct parameters on survival was estimated, founding
that high values of HG and MMSE induced a higher
probability of surviving, while being male, having a low
ADL or a poor SRHS tended to reduce expected survival
time. Furthermore, the presence of a genetic influence on
frailty variance was suggested by the estimation of herit-
ability of the frailty status, where it was found that the
additive genetic component accounts for 43% of the over-
all variability of frailty levels between couple of twins. In
line with previous findings, the estimate was higher in
males than in females, consistent with the hypothesis
that frailty status of men is more related to the genetic
background while the frailty conditions of females are
more dependent on environmental factors. In addition,
as for lifespan, the influence of the genetic component on
frailty status was found higher at advanced ages.
On the whole, this approach, which is based on popula-
tion-specific data under study and does not use any a
priori thresholds, may be very promising for an objective
identification of frail subject. This may be a very important
task for future societies, helping to address specific medi-
cal care, by tailoring treatments on the basis of the real
needs of each single patient, especially of pre-frail and frail
older patients with multiple chronic conditions and
reduced life expectancy, finally preventing the effects of
frailty.
The role of epigenetics in human ageing and longevity
Epigenetic modifications indicate the sum of heritable
changes, such as DNA methylation, histone modification
and miRNA expression, that affect gene expression
without changing the DNA sequence [131]. It is becom-
ing clear that epigenetic information is only partially
stable and destined to change across the lifespan repre-
senting a drawbridge between genetics and environment.
Epigenetic variations have been suggested to have an
important role in cellular senescence, tumorigenesis and
in several diseases including type-2 diabetes, cardiovas-
cular and autoimmune diseases, obesity and Alzheimer
disease [132]. A correlation between epigenetic DNA
modifications and human lifespan has been shown by
Fraga et al. [133], who found that global and locus-spe-
cific differences in DNA methylation in identical twins
of different ages are influenced by environmental factors
and lifestyle. Most studies demonstrated that ageing is
associated with a relaxation of epigenetic control; from
one side, a decrease in global cytosine methylation has
been found during ageing both in vivo and in vitro stu-
dies, mostly due to the demethylation in transposable
repetitive elements [134,135]. On the other hand, an
age-related hypermethylation has been observed in pro-
moter regions of specific genes, such as those genes
involved in cell cycle regulation, tumor-cell invasion,
apoptosis, metabolism, cell signaling and DNA repair,
with a consequent decrease of correspondent mRNA
levels, confirming the potential role of these pathways in
human ageing [136-143]. Moreover, recent studies
reported as different epigenetic profiles can be asso-
ciated with a different quality of ageing. Bellizzi and co-
workers [144], studying the distribution of methylation
pattern in a sample of elderly subjects stratified accord-
ing to their quality of ageing (described by their scores
in specific functional, cognitive and psychological tests),
found that the level of methylation is correlated with
the health status in the elderly. In particular, a signifi-
cant decrease in the global DNA methylation levels was
associated with functional decline, suggesting that the
relaxation of the epigenetic control in ageing is specifi-
cally associated with the functional decline rather than
with the chronological age of individuals. These results
confirm that epigenetic variations, which in turn depend
on hereditary, environmental and stochastic factors, may
play an important role in determining physiological
changes associated to old age.
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Despite the enormous technical progresses, which allow
to analyzed many single variants as well as the coordi-
nated expression of many genes together by high-
throughput platforms, many challenges still remain to
be faced by the researchers trying to identify genetic
and non genetic variants associated with human longev-
ity. A close partnership between gerontologists, epide-
miologists, and geneticists is needed to take full
advantage of emerging genome information and tech-
n o l o g ya n db r i n ga b o u tan e wa g ef o rb i o l o g i c a la g e i n g
research. In addition, we believe that the next future
will see much progresses in our understanding of the
longevity trait, mainly coming from the integration of
genetics and epigenetics information by multidisciplin-
ary approaches, to the aim of obtaining an overall pic-
ture of what successful ageing is.
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